Healthcare costs of stroke and major bleeding in patients with atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants

Heather M. Rozjabek, Craig I. Coleman, Veronica Ashton, François Laliberté, Paul Oyefesobi, Dominique Lejeune, Guillaume Germain, Jeff R. Schein, Zhong Yuan, Patrick Lefebvre & Eric D. Peterson
Objective: To assess long-term healthcare costs related to ischemic stroke and systemic embolism (stroke/SE) and major bleeding (MB) events in patients with non-valvular atrial fibrillation (NVAF) treated with non-vitamin K antagonist oral anticoagulants (NOACs). Materials and methods: Optum’s Clinformatics Data Mart database from 1/2009–12/2016 was analyzed. Adult patients with ≥1 stroke/SE hospitalization (index date) were matched 1:1 to patients without stroke/SE (random index date), based on propensity scores. Patients with an MB event were matched...
This data repository is not currently reporting usage information. For information on how your repository can submit usage information, please see our documentation.